查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933294

全球皮癬菌甲癬治療市場：市場規模、佔有率、成長率、行業分析、依類型、應用和地區劃分的考慮因素以及未來預測（2026-2034 年）

Dermatophytic Onychomycosis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 136 Pages | 商品交期: 請詢問到貨日

價格

皮癬菌甲癬治療市場成長因素

2025 年，全球皮癬菌甲癬治療市場規模為 57.4 億美元。預計該市場將從 2026 年的 61.7 億美元成長至 2034 年的 109.9 億美元，在預測期（2026-2034 年）內複合年增長率 (CAGR) 為 7.49%。

北美地區在 2025 年佔市場主導地位，市佔率達 44.33%，這主要得益於高處方量、強有力的報銷政策以及品牌外用藥物的廣泛應用。

皮癬菌性甲癬 (ONY) 是一種主要由皮癬菌引起的指甲真菌感染，約佔全球所有甲癬病例的 70-80%。此病會導致指甲變色、增厚和脆弱，嚴重影響患者的生活品質。糖尿病盛行率上升、人口老化以及人們對甲癬認識的提高是推動有效治療需求的關鍵因素。

市場概覽

甲癬約佔全球指甲疾病的 50%，全球人口盛行率估計為 5.5%。老年人和糖尿病患者的盛行率更高，因此對局部和口服抗真菌藥物的需求長期存在。由於診斷率的提高、皮膚科醫療服務的可近性改善以及處方藥和非處方藥的廣泛普及，市場持續穩定成長。

由於病患就診量減少和診斷延遲，COVID-19 疫情暫時影響了市場。然而，診所的重新開放、遠距皮膚科諮詢的日益普及以及患者意識的提高，正在推動疫情後的復甦。

市場動態

市場驅動因素

皮癬菌性甲癬盛行率的上升仍然是市場成長的主要驅動因素。據 Moberg Pharma AB 稱，全球約有 10% 的人口患有甲癬，光是美國就有 3,500 萬至 4,000 萬例。此外，糖尿病盛行率的上升也顯著增加了真菌性甲癬的易感性。

另一個關鍵驅動因素是對更安全的治療方案的需求不斷增長。 口服抗真菌藥物與肝毒性有關，因此醫生通常會開立外用指甲油，尤其是在治療輕度至中度感染時。

市場限制因子

認知度低和治療依從性差仍然是主要挑戰。研究表明，口服治療的依從率僅為 45%，而外用治療的依從率僅為 24%，這主要是由於治療週期長和患者教育不足。這些因素阻礙了及時診斷和有效治療，減緩了整體市場成長。

市場趨勢

轉向外用治療

市場的關鍵趨勢是逐漸轉向外用解決方案，包括含藥指甲油。由於全身副作用減少和安全性提高，Juvria（依芬那唑）和環吡酮胺等產品越來越受歡迎。不斷創新以提高藥物對甲床的滲透性進一步強化了這一趨勢。

依細分市場分析

依產品類型

市場依產品類型細分：片劑和指甲油。

預計到2026年，指甲油細分市場將佔主導地位，市佔率達50.29%，這主要得益於外用療法的日益普及以及Jublia的強勁銷售。

由於特比萘芬等口服抗真菌仿製藥的供應不斷增加，預計片劑細分市場將保持穩定成長。

依給藥途徑

預計到2026年，外用藥物將以50.29%的市佔率領先。這主要得益於研發投入的增加以及FDA對多種外用抗真菌候選藥物的批准。口服療法雖然有效，但有安全隱患。

依通路劃分

預計2026年，零售藥局將佔市場主導地位，市佔率達40.62%。這主要得益於非處方藥的高銷售量和不斷擴張的藥局網路。由於疫情後人們購買便利性增加以及行為習慣的改變，預計線上藥局也將實現強勁成長。

區域因素

預計到2025年，北美市場規模將達到25.4億美元，主要得益於處方量高和對品牌藥的強勁需求。

在有利的報銷政策和仿製藥使用量不斷增加的推動下，歐洲的甲癬盛行率為4.3%。

預計亞太地區將以最高的複合年增長率成長，這主要得益於糖尿病盛行率的上升、人口老齡化以及日本、中國和印度新產品的上市。

銷售單位：1,000 單位

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 流行病學：主要國家和地區的皮癬菌性甲癬（2025 年）
  • 主要公司產品線分析
  • 主要公司新產品發布
  • 關鍵產業趨勢：併購、業務合作等等。
  • COVID-19 對市場的影響

第五章 全球皮癬菌甲癬治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品類型劃分
    • 片劑
    • 指甲油
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 外用
  • 市場分析、洞察與預測：依類型劃分
    • 處方藥
    • 非處方藥 (OTC)
  • 市場分析、洞察與預測：依銷售管道劃分
    • 醫院藥房
    • 零售藥房
    • 線上渠道
  • 市場分析，洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 世界其他地區 (ROW)

第六章 北美皮癬菌甲癬治療市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲皮癬菌甲癬治療市場分析：洞察與預測 (2021-2034)

第八章 亞太地區皮癬菌甲癬治療市場分析：洞察與預測 (2021-2034)

章節9.世界其他地區（ROW）皮癬菌甲癬治療市場分析：洞察與預測（2021-2034）

第十章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Galderma
    • Cipla Inc.
    • Janssen Pharmaceuticals, Inc.
    • Kaken Pharmaceuticals Co., Ltd.
Product Code: FBI103310

Growth Factors of dermatophytic onychomycosis treatment Market

The global dermatophytic onychomycosis treatment market was valued at USD 5.74 billion in 2025. The market is projected to grow from USD 6.17 billion in 2026 to USD 10.99 billion by 2034, exhibiting a CAGR of 7.49% during the forecast period (2026-2034).

North America dominated the market in 2025 with a 44.33% share, supported by a high number of prescriptions, strong reimbursement policies, and widespread adoption of branded topical therapies.

Dermatophytic onychomycosis is a fungal nail infection caused primarily by dermatophytes, accounting for nearly 70%-80% of onychomycosis cases globally. The disease leads to nail discoloration, thickening, and brittleness, significantly impacting patient quality of life. Rising prevalence of diabetes, aging populations, and increasing awareness of nail fungal infections are major contributors to the expanding demand for effective treatment options.

MARKET OVERVIEW

Onychomycosis represents nearly 50% of all nail disorders worldwide, with an estimated 5.5% global population prevalence. The condition is more common in elderly individuals and diabetic patients, creating long-term demand for both topical and oral antifungal therapies. The market is witnessing steady growth due to increased diagnosis rates, improved access to dermatology services, and availability of both prescription and OTC treatment options.

The COVID-19 pandemic temporarily impacted the market due to reduced patient visits and delayed diagnosis. However, post-pandemic recovery has been supported by clinic reopenings, growing teledermatology adoption, and increased patient awareness.

MARKET DYNAMICS

Market Drivers

The rising prevalence of dermatophytic onychomycosis remains the primary driver of market growth. According to Moberg Pharma AB, nearly 10% of the global population suffers from onychomycosis, with 35-40 million cases in the U.S. alone. Additionally, the growing diabetic population significantly increases susceptibility to fungal nail infections.

Another key driver is the increasing demand for safer treatment alternatives. Oral antifungal drugs are associated with liver toxicity, leading physicians to favor topical nail lacquers, particularly for mild-to-moderate infections.

Market Restraints

Lack of awareness and poor treatment adherence are major challenges. Studies indicate adherence rates of only 45% for oral therapies and 24% for topical treatments, largely due to long treatment durations and limited patient education. These factors restrict timely diagnosis and effective treatment, slowing overall market growth.

MARKET TRENDS

Shift Toward Topical Therapies

A major trend in the market is the gradual shift toward topical solutions, including medicated nail paints and lacquers. Products such as Jublia (efinaconazole) and ciclopirox are increasingly preferred due to lower systemic side effects and improved safety profiles. Continuous innovation aimed at enhancing nail bed penetration is further strengthening this trend.

SEGMENTATION ANALYSIS

By Product Type

The market is segmented into tablets and nail paints.

The nail paints segment dominated the market in 2026, accounting for 50.29% market share, driven by rising adoption of topical therapies and strong sales of Jublia.

The tablets segment is expected to grow steadily due to increasing availability of generic oral antifungals such as terbinafine.

By Route of Administration

The topical segment led the market in 2026 with a 50.29% share, supported by increasing R&D investments and FDA approvals for topical antifungal candidates. Oral therapies remain effective but are limited by safety concerns.

By Distribution Channel

Retail pharmacies dominated the market in 2026 with a 40.62% share, owing to high OTC drug sales and expanding pharmacy networks. Online pharmacies are expected to witness strong growth due to convenience and post-pandemic behavioral shifts.

REGIONAL INSIGHTS

North America generated USD 2.54 billion in 2025, driven by high prescription volumes and strong demand for branded products.

Europe is supported by favorable reimbursement policies and increasing use of generics, with onychomycosis prevalence at 4.3%.

Asia Pacific is expected to grow at the fastest CAGR due to rising diabetes prevalence, aging populations, and new product launches in Japan, China, and India.

COMPETITIVE LANDSCAPE

The market is moderately consolidated, led by Bausch Health Companies Inc., primarily due to strong sales of Jublia. Other prominent players include Pfizer Inc., Galderma, GlaxoSmithKline plc, Cipla Inc., and Kaken Pharmaceuticals Co., Ltd. Strategic initiatives such as generic launches, licensing agreements, and geographic expansion are shaping competitive dynamics.

CONCLUSION

The global dermatophytic onychomycosis treatment market is experiencing consistent growth, driven by rising disease prevalence, increasing diabetic and geriatric populations, and growing preference for safer topical therapies. With the market expanding from USD 5.74 billion in 2025 to USD 10.99 billion by 2034, advancements in drug formulation, expanding OTC availability, and improved patient access are expected to support long-term market expansion. Continued innovation, growing awareness, and favorable regulatory developments are likely to strengthen the adoption of dermatophytic onychomycosis treatments during the forecast period.

CAGR CAGR of 7.49% from 2026-2034

Unit Volume (K Units)

Segmentation By Product Type

  • Tablets
  • Nail Paints

By Route of Administration

  • Oral
  • Topical

By Type

  • Prescribed
  • Over-the-Counter (OTC)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels

By Geography

  • North America (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Russia
    • Rest of Europe
  • Asia Pacific (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • Southeast Asia
    • Rest of Asia Pacific

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology: Dermatophytic Onychomycosis, Key Countries/ Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions and Partnerships
  • 4.5. Impact of COVID-19 on the Market

5. Global Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Tablets
    • 5.1.2. Nail Paints
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Topical
  • 5.3. Market Analysis, Insights and Forecast - By Type
    • 5.3.1. Prescribed
    • 5.3.2. Over-the-Counter (OTC)
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Channels
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of World

6. North America Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Tablets
    • 6.1.2. Nail Paints
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Topical
  • 6.3. Market Analysis, Insights and Forecast - By Type
    • 6.3.1. Prescribed
    • 6.3.2. Over-the-Counter (OTC)
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Channels
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Tablets
    • 7.1.2. Nail Paints
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Topical
  • 7.3. Market Analysis, Insights and Forecast - By Type
    • 7.3.1. Prescribed
    • 7.3.2. Over-the-Counter (OTC)
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Channels
  • 7.5. Market Analysis, Insights and Forecast - By Countries/ Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Russia
    • 7.5.8. Rest of Europe

8. Asia Pacific Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Tablets
    • 8.1.2. Nail Paints
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Topical
  • 8.3. Market Analysis, Insights and Forecast - By Type
    • 8.3.1. Prescribed
    • 8.3.2. Over-the-Counter (OTC)
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Channels
  • 8.5. Market Analysis, Insights and Forecast - By Countries/ Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. New Zealand
    • 8.5.6. Southeast Asia
    • 8.5.7. Rest of Asia Pacific

9. Rest of World Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Tablets
    • 9.1.2. Nail Paints
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Topical
  • 9.3. Market Analysis, Insights and Forecast - By Type
    • 9.3.1. Prescribed
    • 9.3.2. Over-the-Counter (OTC)
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Channels

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. GlaxoSmithKline plc
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Pfizer Inc.
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Galderma
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Cipla Inc.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Janssen Pharmaceuticals, Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Kaken Pharmaceuticals Co., Ltd.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 4: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 6: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product, 2021-2034
  • Table 7: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 9: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product, 2021-2034
  • Table 12: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 14: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product, 2021-2034
  • Table 17: Table 19: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 19: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Rest of World Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product, 2021-2034
  • Table 22: Rest of World Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Rest of World Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 24: Rest of World Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Dermatophytic Onychomycosis Treatment Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025 & 2034
  • Figure 5: Global Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 7: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Product, 2025 & 2034
  • Figure 8: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product, 2025
  • Figure 9: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 12: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025
  • Figure 13: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 16: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), By Country, 2025
  • Figure 17: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Product, 2025 & 2034
  • Figure 18: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product, 2025
  • Figure 19: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 22: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025
  • Figure 23: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Product, 2025 & 2034
  • Figure 28: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product, 2025
  • Figure 29: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 32: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025
  • Figure 33: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Rest of World Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Product, 2025 & 2034
  • Figure 38: Rest of World Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product, 2025
  • Figure 39: Rest of World Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 40: Rest of World Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Rest of World Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 42: Rest of World Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025
  • Figure 43: Rest of World Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Rest of World Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Global Dermatophytic Onychomycosis Treatment Market Share (%), By Company, 2025